

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Single Technology Appraisal


Venetoclax with obinutuzumab for untreated chronic lymphocytic leukaemia when there is no 17p deletion or TP53 mutation and FCR (fludarabine, cyclophosphamide, rituximab) or BR (bendamustine, rituximab) are suitable [ID6291]

Provisional Consultees Provisional Commentators (no right to submit or appeal) Company General AbbVie (venetoclax) All Wales Therapeutics and Toxicology Centre Patient/carer groups Allied Health Professionals Federation African Caribbean Leukaemia Trust Board of Community Health Councils in • Anthony Nolan Wales Black Health Agency for Equality • • **British National Formulary** Blood Cancer UK Care Quality Commission • • Cancer Black Care Department of Health - Northern Ireland • • Healthcare Improvement Scotland Cancer52 • • Chronic Lymphocytic Leukaemia Medicines and Healthcare products • • Support Association **Regulatory Agency** National Association of Primary Care • DKMS • Follicular Lymphoma Foundation National Pharmacy Association • • Helen Rollason Cancer Charity **NHS** Confederation • Independent Cancer Patients Voice NHS Wales Joint Commissioning • Committee Kevin Kararwa Leukaemia Trust • Leukaemia Cancer Society Scottish Medicines Consortium • Welsh Government Leukaemia Care • Lymphoma Action • Possible comparator companies Macmillan Cancer Support • AstraZeneca UK (acalabrutinib) • Maggie's Centres • Baxter Healthcare (cyclophosphamide) • Marie Curie • Celltrion Healthcare UK (rituximab) • South Asian Health Foundation • • Dr. Reddy's Laboratories UK Specialised Healthcare Alliance • (bendamustine) Tenovus Cancer Care • Janssen-Cilag (a Johnson & Johnson • WMUK Innovative Medicine Company) (ibrutinib) Healthcare professional groups • Pfizer (rituximab) Association of Cancer Physicians • Roche Products (obinutuzumab, • **British Blood Transfusion Society** • rituximab) British Committee for Standards in • Sandoz (cyclophosphamide, rituximab) • Haematology

Provisional Stakeholder List

Provisional stakeholder list for the evaluation of venetoclax with obinutuzumab for untreated chronic lymphocytic leukaemia when there is no 17p deletion or TP53 mutation and FCR (fludarabine, cyclophosphamide, rituximab) or BR (bendamustine, rituximab) are suitable [ID6291] Issue date: March 2025

© National Institute for Health and Care Excellence 2025. All rights reserved. 1 of 3



Provisional Consultees	Provisional Commentators (no right to submit or appeal)
 British Geriatrics Society British Institute of Radiology British Psychosocial Oncology Society British Society for Haematology British Society of Interventional Radiology Cancer Research UK NHS Blood and Transplant Royal College of General Practitioners Royal College of Pathologists Royal College of Physicians Royal College of Radiologists Royal College of Radiologists Royal Society of Medicine Society and College of Radiographers UK CLL Forum UK Clinical Pharmacy Association UK Oncology Nursing Society 	 Sanofi (fludarabine) Seacross Pharmaceuticals (bendamustine) Zentiva (bendamustine) Relevant research groups Cochrane Haematological Malignancies Group Genomics England Institute of Cancer Research Leukaemia Busters Leukaemia UK Lymphoma Research Trust MRC Clinical Trials Unit National Institute for Health Research Associated Public Health groups Public Health Wales UK Health Security Agency
 <u>Others</u> Department of Health and Social Care NHS England 	

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

Definitions:


Consultee or commentator stakeholders are provisional until a signed Confidentiality Agreement & Undertaking form is submitted to NICE at the evaluation stage. Participating stakeholders will be listed on the project information page for the evaluation.

Consultees

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and relevant NHS organisations in England.

Provisional stakeholder list for the evaluation of venetoclax with obinutuzumab for untreated chronic lymphocytic leukaemia when there is no 17p deletion or TP53 mutation and FCR (fludarabine, cyclophosphamide, rituximab) or BR (bendamustine, rituximab) are suitable [ID6291] Issue date: March 2025

© National Institute for Health and Care Excellence 2025. All rights reserved. 2 of 3



The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).

All non-company consultees are invited to submit a statement relevant to the group they are representing, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).

Commentators

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC]); other groups (for example, the NHS Confederation and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.